Advertisement
Table 2 Affected coronary artery status, treatment strategy, and pharmacological therapy at discharge
| Survivor group (n = 189) | Cardiac death group (n = 9) | p -value* | |
|---|---|---|---|
| Number of diseased vessel | NS | ||
| One, n (%) | 80 (42.3) | 2 (22.2) | |
| Two, n (%) | 54 (28.6) | 3 (33.3) | |
| Three, n (%) | 55 (29.1) | 4 (44.5) | |
| Stenosis of LMT, n (%) | 15 (7.9) | 2 (22.2) | NS |
| Multi-vessel, n (%) | 112 (59.3) | 8 (88.9) | NS |
| Target lesion | NS | ||
| LAD, n (%) | 97 (51.3) | 4 (44.5) | |
| LCX, n (%) | 32 (16.9) | 0 (0.0) | |
| RCA, n (%) | 53 (28.1) | 3 (33.3) | |
| LMT, n (%) | 7 (3.7) | 2 (22.2) | |
| Treatment strategy | NS | ||
| PCI (BMS), n (%) | 82 (43.4) | 4 (44.5) | |
| PCI (DES), n (%) | 64 (33.9) | 3 (33.3) | |
| POBA, n (%) | 14 (7.4) | 0 (0.0) | |
| CABG, n (%) | 12 (6.3) | 1 (11.1) | |
| Pharmacological therapy at discharge | |||
| Diuretics, n (%) | 39 (20.6) | 5 (55.6) | 0.03 |
| Anti-platelets, n (%) | 188 (99.5) | 9 (100) | NS |
| Anti-coagulants, n (%) | 15 (7.9) | 2 (22.2) | NS |
| CE inhibitor or ARB, n (%) | 134 (70.9) | 7 (77.8) | NS |
| Beta-blocker, n (%) | 133 (70.4) | 6 (66.7) | NS |
| Calcium-channel blocker, n (%) | 52 (27.5) | 1 (11.1) | NS |
| Statin, n (%) | 171 (90.5) | 6 (66.7) | NS |
| Oral hypoglycemic agents, n (%) | 20 (10.6) | 2 (22.2) | NS |
| Sulfonylurea, n (%) | 5 (2.7) | 1 (11.1) | NS |
| Alpha-glucosidase inhibitor, n (%) | 9 (4.8) | 0 (0.0) | NS |
| DPP-4 inhibitor, n (%) | 8 (4.2) | 2 (22.2) | NS |
| Metformin, n (%) | 4 (2.1) | 0 (0.0) | NS |
| Pioglitazone, n (%) | 6 (3.2) | 0 (0.0) | NS |
| Glinide, n (%) | 0 (0.0) | 0 (0.0) | NS |
| Insulin, n (%) | 2 (1.1) | 0 (0.0) | NS |
| Inotropic agents, n (%) | 4 (2.1) | 0 (0.0) | NS |
